Genetics Institute, Schering-Plough, Wyeth-Ayerst International Inc. deal

Wyeth-Ayerst acquired rights from Schering-Plough to develop and market recombinant interleukin 11 (IL-11) in Europe, Africa

Read the full 169 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE